Shirkadda weyn ee dawooyinka Lilly, oo ah shirkad Mareykan ah iyo Novo Nordisk, oo ah shirkad Danish ah, ayaa si isdaba joog ah ugu dhawaaqay xogta iibka alaabadooda ugu muhiimsan sanadka 2020: Dulaglutide wuxuu noqday daawada TOP1 GLP-1, iyadoo la iibinayo $5.07Bn sanadka 2020, sanad- korodhka sanadka ee 22.8%;Liraglutide Bilawga gelitaanka xilli hoos u dhaca, iibka 2020 wuxuu hoos uga dhacay $4.14Bn ilaa $3.93Bn, hoos u dhac sannadle ah oo ah 5.1%;semaglutide ayaa koray sida ugu dhaqsaha badan, iyadoo iibku uu gaaray $3.72Bn sanadka 2020, sanadba sanadka ka dambeeya kororka 119.9%.
Lilly's dulaglutide (magaca ganacsiga Trulicity®) ayaa la bilaabay 2014 wuxuuna noqday daroogo blockbuster ah oo iib ah $5.07Bn kaliya 6 sano gudahood, isagoo noqday horyaal iibka daawooyinka GLP-1.Alaabta kaliya ee Novo Nordisk ayaa si ku meel gaar ah dib uga dhacday Lilly.Liraglutide (magaca ganacsiga Victoza® iyo Saxenda®), oo la bilaabay 2009, ayaa mar ahayd horyaalnimada iibka ee dawooyinka GLP-1, iibkeedii ugu sarreeyay ee 2017 wuxuu gaadhay $ 4.37Bn, in kasta oo ay jiraan laba calaamadood oo muujinaya nooca II ee sonkorowga iyo buurnaanta. , xogta 2020 waxay muujineysaa in suuqa dawadan uu galay xilli hoos u dhac ah.Isla Novo Nordisk's semaglutide (magacyada ganacsiga Ozempic® iyo Rybelsus®) ayaa si degdeg ah u koray waxayna u kortay dawo kale oo blockbuster ah oo iib ah $3.72Bn saddex sano gudahood.Daawadu waxay leedahay laba nooc oo qiyaas ah oo irbad ah iyo diyaargarowga afka.
Marka loo eego juquraafi ahaan, Mareykanka waa dalka ugu badan ee iibka ah ee liraglutide, isaga oo ku xisaabtamaya ku dhawaad 60% sanadka 2020, sanad kasto hoos u dhac ku yimid 11.02%;sidoo kale waa hoos u dhaca Maraykanka ee kiciyay hoos u dhaca suuqa caalamiga ah ee liraglutide.Gobolka EMEA (Europe, Bariga Dhexe, Afrika) ayaa si tartiib tartiib ah u koray, iyadoo CAGR oo kaliya 1.6% shantii sano ee la soo dhaafay;Shiinaha waa suuqa ugu kobaca badan, iyadoo iibkeedu yahay $182.50Mn sanadka 2020, iyadoo koror sanadeedka kobaciisu yahay 42.39%.Tan iyo markii semaglutide ay suuqa ku jirtay si dhakhso ah, dhammaan suuqyada ayaa ku jira heer kobac degdeg ah.Maraykanku weli waa suuqa ugu weyn, isaga oo ku xisaabtamaya 80.04% iibka sanadka 2020, korodhka sanadba sanadka ka dambeeya 106.08%;EMEA waxay leedahay kaliya 13.64% saamiga laakiin heerka kobaca sanadlaha ah ee 249.65% %.Semaglutide waxaa laga bilaabay Shiinaha sanadka 2020 iyadoo la iibinayo $1.61Mn.Jaantuska 3 ayaa muujinaya xaalada gobolka ee dulaglutide.Sida suuqa ugu weyn, Mareykanka wuxuu leeyahay iib gaar ah oo gaaraya $3.836Bn, taasoo ka dhigan 75.69%, iyadoo kororka kobaca sanadlaha ah uu yahay 79.18%.
Ruqsadaha asaasiga ah ee liraglutide (Victoza® iyo Saxenda®) waxay ka dhaceen Shiinaha waxayna ku dhow yihiin inay ku dhacaan US, Japan iyo Germany.Dagaalka Patent Teva ee Novo Nordisk waa la xaliyay, nooca guud ee Tevana waxa uu diyaar noqon doonaa 2023. Mylan waxa kale oo ay codsi ANDA ka gudbisay FDA ee liraglutide iyada oo sheeganaysa PIV.Iyada oo ay si tartiib tartiib ah u dhacayso rukhsadaha asaasiga ah iyo khatarta soosaarayaasha daawada guud, daawadu waxay si tartiib tartiib ah u geli doontaa xilli hoos u dhac ah.Ruqsadda dhismaha ee Maraykanka ee Trulicity® ma dhacayso illaa 2027, halka shatiyada ka kooban ee waddamada waaweyn ee Yurub iyo Japan aysan dhacayn illaa 2029, ilaalinta patent-ka asaasiga ah ay ka dheer tahay tan liraglutide.Shatiyada asaasiga ah ee semaglutide (Ozempic® iyo Rybelsus®) waxay dhacayaan 2032 ugu dambeyntii, waxaana weli jira qol weyn oo kobaca suuqa, laakiin waqtigeeda dhicitaanka ee Shiinaha waa 2026.
Waqtiga boostada: Jul-25-2022